However, current anti-hedgehog therapies mainly involve Smo inhibitors, which face challenges like drug resistance and the inability to effectively penetrate the stromal barrier, thus limiting their success in treating pancreatic cancer [33]. The gene discussed is SMO; the disease is pancreatic neoplasm.